Class summary at a glance.

Every drug in the Retinoid class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 19tracked in Part D
CY24 Part D spend: $154.6Mcombined across class
Total Rx claims: 563K278K unique beneficiaries
Generic mfrs (active): 52across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Bexarotene

Brand: Targretin · 11K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 1999-12-29

8 generic mfrs 641 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $77.9M

Class share

50%

of class CY24 spend

View profile →

Tretinoin

Brand: Altreno · 421K Part D claims (CY24) · 227K beneficiaries · First FDA approval: 1973-01-26

9 generic mfrs 1612 plans require PA

Low NADAC$0.797

→

Avg plan cost$2.61

Part D spend $33.1M 3× spread, current vs floor

Class share

21%

of class CY24 spend

View profile →

Acitretin

68K Part D claims (CY24) · 18K beneficiaries · First FDA approval: 2013-07-19

6 generic mfrs 330 plans require PA

Low NADAC$2.20

→

Avg plan cost$4.08

Part D spend $20.7M 2× spread, current vs floor

Class share

13%

of class CY24 spend

View profile →

Tazarotene

Brand: Arazlo · 21K Part D claims (CY24) · 12K beneficiaries · First FDA approval: 2017-03-10

4 generic mfrs 588 plans require PA

Low NADAC$1.84

→

Avg plan cost$6.57

Part D spend $6.1M 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Palovarotene

Brand: SOHONOS · 57 Part D claims (CY24) · First FDA approval: 2023-08-16

Brand-only (no generics) 85 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $5.3M

Class share

of class CY24 spend

View profile →

Adapalene

Brand: DIFFERIN · 15K Part D claims (CY24) · 8K beneficiaries · First FDA approval: 2009-09-15

6 generic mfrs 34 plans require PA

Low NADAC$0.495

→

Avg plan cost$2.11

Part D spend $4.9M 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Isotretinoin

Brand: ACCUTANE · 26K Part D claims (CY24) · 11K beneficiaries · First FDA approval: 2002-11-11

8 generic mfrs 2214 plans require PA

Low NADAC$1.71

→

Avg plan cost$7.06

Part D spend $4.7M 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Alitretinoin

Brand: PANRETIN · 247 Part D claims (CY24) · 113 beneficiaries · First FDA approval: 2019-09-10

Brand-only (no generics) 219 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $1.5M

Class share

of class CY24 spend

View profile →

Trifarotene

Brand: AKLIEF · 529 Part D claims (CY24) · 293 beneficiaries · First FDA approval: 2019-10-04

Brand-only (no generics) 1 plans require PA

Low NADAC$16.34

→

Avg plan cost$16.34

Part D spend $377909 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Adapalene Gel Usp,

— Part D claims (CY24) · First FDA approval: 2023-05-05

Brand-only (no generics)

Low NADAC$0.495

→

Avg plan cost$0.726

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Adapalene and Benzoyl Peroxide

Brand: EPIDUO · — Part D claims (CY24) · First FDA approval: 2008-12-08

7 generic mfrs 6 plans require PA

Low NADAC$0.285

→

Avg plan cost$2.10

Part D spend — 7× spread, current vs floor

Class share

of class CY24 spend

View profile →

Adapalene and Benzoyl Peroxide Gel,

— Part D claims (CY24) · First FDA approval: 2023-08-14

Brand-only (no generics)

Low NADAC$0.285

→

Avg plan cost$0.285

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Adapalene and Benzoyl Peroxide Topical

Brand: ADAPALENE AND BENZOYL PEROXIDE · — Part D claims (CY24) · First FDA approval: 2022-08-10

Brand-only (no generics)

Low NADAC$0.626

→

Avg plan cost$0.626

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Benzoyl Peroxide and Tretinoin

Brand: Twyneo · — Part D claims (CY24) · First FDA approval: 2025-08-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Clindamycin Phosphate/Benzoyl Peroxide/Adapalene

Brand: Cabtreo · — Part D claims (CY24) · First FDA approval: 2023-10-20

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Clindamycin and Tretinoin

Brand: ZIANA · — Part D claims (CY24) · First FDA approval: 2006-12-01

3 generic mfrs 2 plans require PA

Low NADAC$3.44

→

Avg plan cost$4.07

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Clindamycin and Tretinoin Gel

— Part D claims (CY24) · First FDA approval: 2023-09-04

Brand-only (no generics)

Low NADAC$3.44

→

Avg plan cost$4.07

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Halobetasol and Tazarotene

Brand: Duobrii · — Part D claims (CY24) · First FDA approval: 2019-04-25

1 generic mfrs 3 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Tretinoin and Benzoyl Peroxide

Brand: TWYNEO · — Part D claims (CY24) · First FDA approval: 2022-03-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.